RAY LIN: Open Payments
NPI 1649693540 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,858 in 104 payments from 13 companies in 2025. Trend: 2023 $2,343 · 2024 $3,370 · 2025 $2,858
Food & beverage: $2,759Education: $99
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $449 |
| Regeneron Healthcare Solutions, Inc. | 7 | $409 |
| ABBVIE INC. | 16 | $391 |
| LEO Pharma Inc. | 13 | $371 |
| Amgen Inc. | 12 | $341 |
| Novartis Pharmaceuticals Corporation | 12 | $256 |
| Arcutis Biotherapeutics, Inc. | 12 | $201 |
| Incyte Corporation | 10 | $193 |
| UCB, Inc. | 3 | $130 |
| Organon LLC | 2 | $43 |
Products named: DUPIXENT, SKYRIZI, ADBRY, OTEZLA, Zoryve, OPZELURA, COSENTYX, Bimzelx.
Industry payments across CA — which companies pay providers there.
